Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00842504 · ClinicalTrials.gov registry record · Phase 1

Alternate Day Micafungin: A PK Study in Pediatric Patients

A Phase 1 study of Fungal Infection, sponsored by Children's Hospital Medical Center, Cincinnati.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT00842504 is a Phase 1 study of Fungal Infection that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 15 participants, below the 160-participant average among 6 other Fungal Infection trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00842504, a Phase 1 study of Fungal Infection, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the pharmacokinetics of micafungin when it is given on an every other day schedule. The study will determine if every other day micafungin will provide drug exposure equivalent to daily dosing while reducing administration costs and improving patient convenience. Fifteen patients will be enrolled on this study. Blood samples for PK measurements will be obtained for 48 hours following a single dose of micafungin (3 mg/kg).

Conditions Studied

Interventions

  • DRUG Micafungin

Study Locations (1)

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2007-07
Est. Completion 2009-12
Phase Phase 1

What the Registry Record Tells You About NCT00842504

The ClinicalTrials.gov registry entry for NCT00842504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 6 other Fungal Infection trials with a reported enrollment target (91% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fungal Infection appearing as the primary indexed condition, and to 1 intervention - of which Micafungin is the first listed.

NCT00842504 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00842504 about?

NCT00842504 is a clinical study titled "Alternate Day Micafungin: A PK Study in Pediatric Patients". The purpose of this study is to examine the pharmacokinetics of micafungin when it is given on an every other day schedule. The study will determine if every other day micafungin will provide drug exposure equivalent to daily dosing while reducing administration costs and improving patient convenien...

What is the current status of trial NCT00842504?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-07. Estimated completion is 2009-12.

What conditions does trial NCT00842504 study?

This clinical trial studies the following conditions: Fungal Infection.

What interventions are being tested in trial NCT00842504?

The interventions under investigation include: Micafungin (DRUG).

Who is sponsoring clinical trial NCT00842504?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00842504 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fungal Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.